Formulation and In Vitro Evaluation of Bilayer Tablets of Nebivolol Hydrochloride and Nateglinide for the Treatment of Diabetes and Hypertension

Table 14

Evaluation parameters of Nateglinide sustained release tablets.

Batch code	Weight variation (%)	Hardness (kg/cm^2)	Thickness (mm)	Friability (%)	Drug content (%)
N1	0.22	7.0	3.97	0.59	96.12
N2	0.89	5.8	3.95	0.62	97.45
N3	0.55	7.2	3.99	0.60	98.10
N4	1.55	6.8	3.85	0.54	95.53
N5	1.20	6.2	3.57	0.70	98.63
N6	0.89	5.5	3.84	0.69	98.84
N7	0.22	6.5	3.73	0.72	97.14
N8	0.22	5.5	3.69	0.54	101.15
N9	0.55	6.8	3.89	0.52	98.68
N10	1.55	5.4	3.91	0.63	102.42
N11	0.89	6.5	4.11	0.71	97.85
N12	1.88	7.0	3.90	0.51	96.81
N13	1.20	6.0	3.66	0.56	100.65